Abstract

In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and translational studies to better define the purported therapeutic advantage of NUC-1031 over gemcitabine. That would be a more cautious approach than the phase III clinical trial which is planning to enrol 828 patients with biliary tract tumours to compare gemcitabine/cisplatin "conventional" treatment with or without NUC-1031.

Original languageEnglish
Pages (from-to)1011-1014
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume85
Issue number6
DOIs
Publication statusPublished - 1 Jun 2020

Cite this